共 1751 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 359 1367-1380
[2]
Ferlay J(2008)Lung cancer N Engl J Med 353 123-132
[3]
Soerjomataram I(2005)Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 361 947-957
[4]
Siegel RL(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 362 2380-2388
[5]
Torre LA(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 17 577-589
[6]
Jemal A(2016)Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Lancet Oncol 378 113-125
[7]
Herbst Roy S(2018)Osimertinib in untreated EGFR-mutated advanced non-small-cell Lung cancer N Engl J Med 363 1693-1703
[8]
Heymach JV(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 355 2542-2550
[9]
Lippman SM(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 372 2018-2028
[10]
Shepherd FA(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 387 1540-1550